Levetiracetam in spinal cord injury pain: a randomized controlled trial

N B Finnerup, J Grydehøj, J Bing, I L Johannesen, F Biering-Sørensen, S H Sindrup, Troels Staehelin Jensen

Research output: Contribution to journalJournal articleResearchpeer-review

Abstract

Study design:A randomized, double-blind, placebo-controlled, crossover, multicenter trial. A 1-week baseline period was followed by two treatment periods of 5 weeks duration with levetiracetam increased from 500 mg b.i.d. to a maximum of 1500 mg b.i.d. separated by a 1-week washout period.Objectives:The objective of the study was primarily to evaluate the efficacy of the anticonvulsant levetiracetam in patients with spinal cord injury (SCI) at- and below-level pain and secondarily to evaluate the effect on spasm severity.Setting:Outpatients at two spinal cord units and a pain center.Methods:Patients were allowed to continue their usual pain treatment at a constant dose. The primary outcome measure was the change in median daily pain score (on a 0-10 point numeric rating scale) from 1-week baseline period to the last week of each treatment period. Secondary outcome measures included pain relief of at- and below-level pain, allodynia, spasms and spasticity.Results:A total of 36 patients with SCI at- and or below-level pain were enrolled. Of these, 24 patients completed the trial. We found no effect of levetiracetam on the primary (P=0.46) or any of the secondary outcome measures. Only two patients continued levetiracetam treatment following the trial, and one patient was still in levetiracetam treatment at the 6-month follow-up. Levetiracetam was generally well tolerated with no serious adverse events.Conclusions:Levetiracetam does not relieve neuropathic pain or spasm severity following spinal cord injury.Spinal Cord advance online publication, 9 June 2009; doi:10.1038/sc.2009.55.
Original languageEnglish
JournalSpinal Cord
Volume47
Pages (from-to)861-867
ISSN1362-4393
DOIs
Publication statusPublished - 9. Jun 2009

Fingerprint

Randomized Controlled Trials
Outcome Assessment (Health Care)
Pain Clinics
Hyperalgesia
Cross-Over Studies
Multicenter Studies
Publications
Outpatients
Placebos

Cite this

Finnerup, N. B., Grydehøj, J., Bing, J., Johannesen, I. L., Biering-Sørensen, F., Sindrup, S. H., & Jensen, T. S. (2009). Levetiracetam in spinal cord injury pain: a randomized controlled trial. Spinal Cord, 47, 861-867. https://doi.org/10.1038/sc.2009.55
Finnerup, N B ; Grydehøj, J ; Bing, J ; Johannesen, I L ; Biering-Sørensen, F ; Sindrup, S H ; Jensen, Troels Staehelin. / Levetiracetam in spinal cord injury pain: a randomized controlled trial. In: Spinal Cord. 2009 ; Vol. 47. pp. 861-867.
@article{fa3afc20a1d111de9743000ea68e967b,
title = "Levetiracetam in spinal cord injury pain: a randomized controlled trial",
abstract = "Study design:A randomized, double-blind, placebo-controlled, crossover, multicenter trial. A 1-week baseline period was followed by two treatment periods of 5 weeks duration with levetiracetam increased from 500 mg b.i.d. to a maximum of 1500 mg b.i.d. separated by a 1-week washout period.Objectives:The objective of the study was primarily to evaluate the efficacy of the anticonvulsant levetiracetam in patients with spinal cord injury (SCI) at- and below-level pain and secondarily to evaluate the effect on spasm severity.Setting:Outpatients at two spinal cord units and a pain center.Methods:Patients were allowed to continue their usual pain treatment at a constant dose. The primary outcome measure was the change in median daily pain score (on a 0-10 point numeric rating scale) from 1-week baseline period to the last week of each treatment period. Secondary outcome measures included pain relief of at- and below-level pain, allodynia, spasms and spasticity.Results:A total of 36 patients with SCI at- and or below-level pain were enrolled. Of these, 24 patients completed the trial. We found no effect of levetiracetam on the primary (P=0.46) or any of the secondary outcome measures. Only two patients continued levetiracetam treatment following the trial, and one patient was still in levetiracetam treatment at the 6-month follow-up. Levetiracetam was generally well tolerated with no serious adverse events.Conclusions:Levetiracetam does not relieve neuropathic pain or spasm severity following spinal cord injury.Spinal Cord advance online publication, 9 June 2009; doi:10.1038/sc.2009.55.",
author = "Finnerup, {N B} and J Grydeh{\o}j and J Bing and Johannesen, {I L} and F Biering-S{\o}rensen and Sindrup, {S H} and Jensen, {Troels Staehelin}",
year = "2009",
month = "6",
day = "9",
doi = "10.1038/sc.2009.55",
language = "English",
volume = "47",
pages = "861--867",
journal = "Spinal Cord",
issn = "1362-4393",
publisher = "Nature Publishing Group",

}

Finnerup, NB, Grydehøj, J, Bing, J, Johannesen, IL, Biering-Sørensen, F, Sindrup, SH & Jensen, TS 2009, 'Levetiracetam in spinal cord injury pain: a randomized controlled trial', Spinal Cord, vol. 47, pp. 861-867. https://doi.org/10.1038/sc.2009.55

Levetiracetam in spinal cord injury pain: a randomized controlled trial. / Finnerup, N B; Grydehøj, J; Bing, J; Johannesen, I L; Biering-Sørensen, F; Sindrup, S H; Jensen, Troels Staehelin.

In: Spinal Cord, Vol. 47, 09.06.2009, p. 861-867.

Research output: Contribution to journalJournal articleResearchpeer-review

TY - JOUR

T1 - Levetiracetam in spinal cord injury pain: a randomized controlled trial

AU - Finnerup, N B

AU - Grydehøj, J

AU - Bing, J

AU - Johannesen, I L

AU - Biering-Sørensen, F

AU - Sindrup, S H

AU - Jensen, Troels Staehelin

PY - 2009/6/9

Y1 - 2009/6/9

N2 - Study design:A randomized, double-blind, placebo-controlled, crossover, multicenter trial. A 1-week baseline period was followed by two treatment periods of 5 weeks duration with levetiracetam increased from 500 mg b.i.d. to a maximum of 1500 mg b.i.d. separated by a 1-week washout period.Objectives:The objective of the study was primarily to evaluate the efficacy of the anticonvulsant levetiracetam in patients with spinal cord injury (SCI) at- and below-level pain and secondarily to evaluate the effect on spasm severity.Setting:Outpatients at two spinal cord units and a pain center.Methods:Patients were allowed to continue their usual pain treatment at a constant dose. The primary outcome measure was the change in median daily pain score (on a 0-10 point numeric rating scale) from 1-week baseline period to the last week of each treatment period. Secondary outcome measures included pain relief of at- and below-level pain, allodynia, spasms and spasticity.Results:A total of 36 patients with SCI at- and or below-level pain were enrolled. Of these, 24 patients completed the trial. We found no effect of levetiracetam on the primary (P=0.46) or any of the secondary outcome measures. Only two patients continued levetiracetam treatment following the trial, and one patient was still in levetiracetam treatment at the 6-month follow-up. Levetiracetam was generally well tolerated with no serious adverse events.Conclusions:Levetiracetam does not relieve neuropathic pain or spasm severity following spinal cord injury.Spinal Cord advance online publication, 9 June 2009; doi:10.1038/sc.2009.55.

AB - Study design:A randomized, double-blind, placebo-controlled, crossover, multicenter trial. A 1-week baseline period was followed by two treatment periods of 5 weeks duration with levetiracetam increased from 500 mg b.i.d. to a maximum of 1500 mg b.i.d. separated by a 1-week washout period.Objectives:The objective of the study was primarily to evaluate the efficacy of the anticonvulsant levetiracetam in patients with spinal cord injury (SCI) at- and below-level pain and secondarily to evaluate the effect on spasm severity.Setting:Outpatients at two spinal cord units and a pain center.Methods:Patients were allowed to continue their usual pain treatment at a constant dose. The primary outcome measure was the change in median daily pain score (on a 0-10 point numeric rating scale) from 1-week baseline period to the last week of each treatment period. Secondary outcome measures included pain relief of at- and below-level pain, allodynia, spasms and spasticity.Results:A total of 36 patients with SCI at- and or below-level pain were enrolled. Of these, 24 patients completed the trial. We found no effect of levetiracetam on the primary (P=0.46) or any of the secondary outcome measures. Only two patients continued levetiracetam treatment following the trial, and one patient was still in levetiracetam treatment at the 6-month follow-up. Levetiracetam was generally well tolerated with no serious adverse events.Conclusions:Levetiracetam does not relieve neuropathic pain or spasm severity following spinal cord injury.Spinal Cord advance online publication, 9 June 2009; doi:10.1038/sc.2009.55.

U2 - 10.1038/sc.2009.55

DO - 10.1038/sc.2009.55

M3 - Journal article

VL - 47

SP - 861

EP - 867

JO - Spinal Cord

JF - Spinal Cord

SN - 1362-4393

ER -

Finnerup NB, Grydehøj J, Bing J, Johannesen IL, Biering-Sørensen F, Sindrup SH et al. Levetiracetam in spinal cord injury pain: a randomized controlled trial. Spinal Cord. 2009 Jun 9;47:861-867. https://doi.org/10.1038/sc.2009.55